샘플 요청 목록

 카트 문의
시장보고서
상품코드
1563827

세계의 캐리어 스크리닝 시장

Carrier Screening
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 173 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

캐리어 스크리닝 시장은 2030년까지 78억 달러에 도달할 전망입니다.

2023년에 28억 달러로 추정된 캐리어 스크리닝 시장은 예측 기간 동안 복합 연간 성장률(CAGR) 15.7%로 성장하고 2030년에는 78억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 유전성 질환은 복합 연간 성장률(CAGR) 18.8%로 성장을 지속하고, 분석 기간 종료까지 30억 달러에 달할 것으로 예측됩니다. 낭포성 섬유증 분절의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 16.6%로 추정됩니다.

미국 시장은 7억 5,680만 달러로 추정, 중국은 복합 연간 성장률(CAGR) 21.5%로 성장할 것으로 예측됩니다.

미국 캐리어 스크리닝 시장은 2023년 7억 5,680만 달러로 추정됐습니다. 세계의 2위 경제대국인 중국은 2030년까지 19억 달러 규모에 이를 것으로 예측되며 예측 기간 동안 복합 연간 성장률(CAGR)은 21.5%입니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR)은 각각 11.1%와 13.4%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 약 12.4%로 성장할 것으로 예측됩니다.

세계의 경력 및 스크리닝 시장 - 주요 동향 및 촉진요인 요약

왜 캐리어 스크리닝은 현대 건강 관리에서 중요한 도구인가?

캐리어 스크리닝은 중요한 유전자 검사 과정이며, 개인과 부부가 특정 유전 질환의 유전자를 가지고 있는지 여부를 결정하는 데 도움이 됩니다. 이 스크리닝은 자궁 축농증, 테이삭스병, 겸상 적혈구 빈혈 등의 유전성 질환을 아이에게 계승시킬 위험을, 앞으로 부모가 되는 사람이 평가할 수 있도록 하는 것으로, 생식 계획에 있어서 중요한 역할을 연주합니다. 유전적 건강에 대한 인식이 높아짐에 따라, 캐리어 스크리닝은 임신 전 출산 전 케어의 기초가 되어, 개인이 충분한 정보를 얻은 후에 생식에 관한 결정을 내릴 기회를 제공합니다. 개인화 및 예방 의학이 기세를 늘리는 시대에 캐리어 스크리닝은 조기 발견과 적극적인 건강 관리를 위한 강력한 도구를 제공하여 가족이 임신 전에 위험을 완화할 수 있게 합니다. 캐리어 스크리닝의 가치는 유전자에 대한 자세한 인사이트을 제공하고 유전적 궁합을 이해하는 데 도움이 됩니다. 이 정보는 유전 상담, 유전학적 검사를 수반하는 체외수정(IVF)과 같은 보조생식기술 기술, 또는 다른 생식 전략과 같은 충분한 정보를 기반으로 한 선택으로 커플을 안내 할 수 있습니다. 유전자 기술이 발전하고 스크리닝으로 확인할 수 있는 질병의 수가 증가함에 따라, 캐리어 스크리닝은 점점 더 주류가 되고 있으며, 더 많은 가족들이 심각한 질병의 전달을 막을 수 있는 중요한 유전자 정보에 액세스할 수 있습니다.

기술의 진보는 캐리어 스크리닝을 어떻게 향상시켰습니까?

혁신은 캐리어 스크리닝을 크게 개선하여 보다 빠르고 합리적인 가격으로 더욱 종합적으로 만들었습니다. 가장 혁신적인 발전 중 하나는 차세대 시퀀서(NGS)로 여러 유전자를 동시에 분석할 수 있게 되어 비용을 절감하면서 스크리닝되는 질환의 범위가 넓어졌습니다. NGS는 더욱 광범위하고 상세한 캐리어 스크리닝 패널을 이용할 수 있게 되었고, 1회 분석으로 수백 개의 유전자 질환을 검사할 수 있게 되었습니다. 이를 통해 캐리어 스크리닝의 정확성과 범위를 획기적으로 개선하고 부부가 유전 위험을 종합적으로 이해하고 가족 계획에 대한 충분한 정보를 바탕으로 결정을 내릴 수 있습니다. 가정용 유전자 검사 키트의 대두도 캐리어 스크리닝에의 액세스에 혁명을 가져오고, 개인이 집에서 DNA 샘플을 채취해, 인정 실험실에 보내서 분석하는 것을 가능하게 했습니다. 이 키트의 편의성과 가용성은 더 많은 사람들이 위치에 관계없이 유전자 검사를 받기 쉬워졌습니다. 바이오인포매틱스에 의한 유전자 데이터 분석의 개선과 함께 인공지능(AI)의 통합은 검사 결과의 정확도를 더욱 높여 인위적 실수 가능성을 줄이고, 보다 신속하고 신뢰성 높은 유전학적 인사이트을 제공합니다. AI가 지속적으로 진화함에 따라 캐리어 스크리닝 검사 결과의 정확성과 예측력을 향상시키고 생식 의학에서의 사용을 더욱 확대하는 데 AI는 더욱 중요한 역할을 할 것으로 예상됩니다.

캐리어 스크리닝 시장에 영향을 주는 새로운 동향이란?

기술의 진보와 건강 관리의 우선 순위 변화로 인해 유전자 검사에 대한 접근 방식이 변화하고 있기 때문에 현재 몇 가지 중요한 동향이 캐리어 스크리닝 시장을 형성하고 있습니다. 중요한 동향 중 하나는 보다 광범위한 유전자 질환이 검사 패널에 포함되는 확장 캐리어 스크리닝으로의 움직임입니다.전통적으로 운반체 스크리닝은 제한된 질병에 초점을 맞추었지만, 기술의 진보로 현재 한 번의 검사로 수백 가지 유전자 질환을 포함할 수 있습니다. 이러한 확대된 스크리닝 접근법은 유전적 위험을 보다 종합적으로 파악할 수 있으며, 개인 및 의료 제공업체가 더 많은 정보를 바탕으로 의사 결정을 내릴 수 있기 때문에 인기를 끌고 있습니다. 또 다른 새로운 동향은 맞춤형 의료에 대한 캐리어 스크리닝의 통합입니다. 건강 관리가 맞춤 치료 계획으로 이동하는 동안, 유전자 검사는 생식계획뿐만 아니라 유전 질환을 발병하기 전에 예방하는데도 사용됩니다. 게다가 캐리어 스크리닝은 민족적 배경이나 가족력에 관계없이 자녀를 보유하고자 하는 모든 사람들에게 보편적인 서비스로 권장되고 있습니다. 이러한 캐리어 스크리닝 보편화의 동향은 더 위험한 부부가 조기에 확인되고 그 자손에게 심각한 유전 질환이 유전 될 가능성을 줄이기위한 적극적인 조치를 취하는 것입니다. 할 수 있도록 도와줍니다. 캐리어 스크리닝과 함께 유전 상담의 역할이 커지고 있다는 것도 주목할 가치가 있습니다. 캐리어 스크리닝 결과가 복잡해짐에 따라 유전 상담원은 이 과정에 필수적인 존재가 되고 있으며, 개인이 결과를 해석하고 생식 건강에 미치는 영향을 이해하는 데 도움이 됩니다. 또한 온라인 포털 및 원격 의료와 같은 디지털 도구의 시작으로 개인이 캐리어 스크리닝과 유전 상담 서비스 모두에 원격으로 액세스할 수 있으며 이러한 필수 의료 서비스의 범위가 더욱 넓어졌습니다.

캐리어 스크리닝 시장 성장의 요인은?

캐리어 스크리닝 시장의 성장은 주로 유전 기술의 진보, 유전성 질환에 대한 의식 증가, 건강 관리 관행의 진화와 관련된 여러 요인에 의해 야기됩니다. 주요 촉진요인 중 하나는 가족 계획에서 유전 건강의 중요성에 대한 인식 증가입니다. 유전학이 질병 예방에 맡기는 역할을 더 많은 사람들이 이해함에 따라 캐리어 스크리닝에 대한 수요가 현저하게 증가하고 있습니다. 건강 관리 제공업체와 유전 카운슬러의 계몽 활동을 통해 캐리어 스크리닝은 특히 유전 질환을 유발할 위험이 있는 부부의 경우 임신 전 및 출산 전 치료에 필수적인 역할을 합니다. 유전 검사 기술, 특히 차세대 시퀀싱(NGS)의 발전으로 캐리어 스크리닝 비용과 납기가 단축되어 더 많은 사람들이 사용할 수있게되었습니다. 이러한 기술적 향상은 집에서 유전자 검사 키트의 편의성과 함께 진입 장벽을 낮추고 더 많은 개인이 생식 건강을 관리하기 위해 적극적으로 행동하도록 촉구합니다. 게다가 앞으로 부모가 되고자 하는 모든 사람에게 헬스케어 전문가가 추천하는 유니버설 캐리어 스크리닝의 동향은 유전자 검사 서비스를 요구하는 사람의 수를 늘려 시장을 확대하고 있습니다. 규제와 보험 적용 범위의 개선도 시장 성장의 원동력이 되고 있습니다. 현재 많은 나라에서 캐리어 스크리닝에 대한 보험 상환이 이루어지고 있으며, 개인에게 보다 저렴한 가격이 되고 있습니다. 게다가, 일상적인 생식 의료 서비스의 일환으로 캐리어 스크리닝을 채택하는 의료 서비스 제공업체가 늘어남에 따라 시장은 지속적으로 확대될 전망이고 있습니다. 마지막으로, 개인의 유전자 프로파일에 맞게 의료를 실시하는 맞춤형 의료 및 예방 의료의 대두에 의해 캐리어 스크리닝은 장래 세대에 보다 건강한 결과를 가져오기 위한 중요한 툴로서 자리매김되고 있습니다.이러한 요인은 유전자 조사의 지속적인 혁신과 함께 세계의 캐리어 스크리닝의 지속적인 성장과 채택을 뒷받침하고 있습니다.

조사 대상 기업 예(전 42건)

  • 23andMe, Inc.
  • Abbott Laboratories
  • AutoGenomics, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Luminex Corporation
  • Myriad Genetics, Inc.
  • Sequenom, Inc.
  • Thermo Fisher Scientific, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

BJH 24.10.08

Global Carrier Screening Market to Reach US$7.8 Billion by 2030

The global market for Carrier Screening estimated at US$2.8 Billion in the year 2023, is expected to reach US$7.8 Billion by 2030, growing at a CAGR of 15.7% over the analysis period 2023-2030. Genetic Disorders, one of the segments analyzed in the report, is expected to record a 18.8% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Cystic Fibrosis segment is estimated at 16.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$756.8 Million While China is Forecast to Grow at 21.5% CAGR

The Carrier Screening market in the U.S. is estimated at US$756.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 21.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.1% and 13.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.4% CAGR.

Global Carrier Screening Market - Key Trends and Drivers Summarized

Why Is Carrier Screening a Vital Tool in Modern Healthcare?

Carrier screening is a critical genetic testing process that helps individuals and couples determine if they carry genes for certain inherited disorders, even if they show no symptoms themselves. This screening plays a vital role in reproductive planning, allowing prospective parents to assess the risk of passing genetic conditions, such as cystic fibrosis, Tay-Sachs disease, and sickle cell anemia, to their children. With increasing awareness of genetic health, carrier screening has become a cornerstone of preconception and prenatal care, offering individuals a chance to make informed reproductive decisions. In an era where personalized medicine and preventive care are gaining momentum, carrier screening offers a powerful tool for early detection and proactive health management, allowing families to mitigate risks before conception. The value of carrier screening lies in the detailed genetic insights it provides, helping people understand their genetic compatibility. This information can guide couples toward informed choices such as genetic counseling, assisted reproductive technologies like in vitro fertilization (IVF) with genetic testing, or other reproductive strategies. As genetic technologies advance and the number of conditions identifiable through screening expands, carrier screening is becoming increasingly mainstream, ensuring that more families have access to crucial genetic information that can prevent the transmission of severe disorders.

How Have Technological Advances Enhanced Carrier Screening?

Technological innovations have significantly improved carrier screening, making it faster, more affordable, and more comprehensive. One of the most transformative advancements is next-generation sequencing (NGS), which allows for the analysis of multiple genes simultaneously, increasing the scope of conditions screened for while reducing costs. With NGS, broader and more detailed carrier screening panels are available, testing for hundreds of genetic conditions in a single analysis. This has dramatically improved the accuracy and scope of carrier screening, ensuring that couples receive a comprehensive understanding of their genetic risks and can make well-informed decisions regarding family planning. The rise of at-home genetic testing kits has also revolutionized access to carrier screening, allowing individuals to collect DNA samples at home and send them to certified labs for analysis. The convenience and accessibility of these kits have made it easier for a larger population to undergo genetic testing, regardless of their location. Along with improvements in genetic data analysis through bioinformatics, the integration of artificial intelligence (AI) is further enhancing the precision of test results, reducing the potential for human error, and offering faster, more reliable genetic insights. As AI continues to evolve, it is expected to play an even more critical role in improving the accuracy and predictive power of carrier screening results, further expanding its use in reproductive health.

What Emerging Trends Are Impacting the Carrier Screening Market?

Several important trends are currently shaping the carrier screening market, as advancements in technology and shifting healthcare priorities drive changes in how genetic testing is approached. One of the key trends is the move toward expanded carrier screening, where a broader range of genetic conditions is included in testing panels. Traditionally, carrier screening focused on a limited set of disorders, but advancements in technology now allow for the inclusion of hundreds of genetic conditions in a single test. This expanded screening approach is gaining popularity as it provides a more comprehensive picture of genetic risks, enabling individuals and healthcare providers to make more informed decisions. Another emerging trend is the integration of carrier screening into personalized medicine. As the healthcare landscape shifts toward individualized treatment plans, genetic testing is being used not only for reproductive planning but also to prevent genetic conditions before they develop. In addition, carrier screening is increasingly being recommended as a universal service for all individuals planning to have children, regardless of ethnic background or family history. This trend toward universal carrier screening is helping to ensure that more at-risk couples are identified early, allowing for proactive measures to be taken to reduce the likelihood of transmitting serious genetic conditions to their offspring. The growing role of genetic counseling alongside carrier screening is also noteworthy. As the complexity of carrier screening results increases, genetic counselors are becoming integral to the process, helping individuals interpret results and understand the implications for their reproductive health. Additionally, the rise of digital tools, such as online portals and telemedicine, is making it easier for individuals to access both carrier screening and genetic counseling services remotely, further expanding the reach of this essential healthcare service.

What Factors Are Behind the Growth of the Carrier Screening Market?

The growth in the carrier screening market is driven by several factors, primarily linked to advances in genetic technologies, increased awareness of genetic disorders, and evolving healthcare practices. One of the key drivers is the growing awareness of the importance of genetic health in family planning. As more people understand the role genetics plays in disease prevention, the demand for carrier screening has increased significantly. Educational efforts from healthcare providers and genetic counselors have helped normalize carrier screening as an essential part of preconception and prenatal care, particularly for couples who are at risk of passing on genetic disorders. Advancements in genetic testing technologies, especially next-generation sequencing (NGS), have reduced the cost and turnaround time for carrier screening, making it more accessible to a broader population. These technological improvements, combined with the convenience of at-home genetic testing kits, have lowered barriers to entry, encouraging more individuals to take proactive steps in managing their reproductive health. Moreover, the trend toward universal carrier screening, recommended by healthcare professionals for all prospective parents, has expanded the market by increasing the number of people seeking genetic testing services. Regulatory and insurance coverage improvements have also fueled market growth. Many countries now offer insurance reimbursement for carrier screening, making it more affordable for individuals. Additionally, as more healthcare providers adopt carrier screening as part of routine reproductive health services, the market is poised for continued expansion. Finally, the rise of personalized and preventive medicine, where healthcare is tailored to individual genetic profiles, is positioning carrier screening as a critical tool for ensuring healthier outcomes for future generations. These factors, along with ongoing innovations in genetic research, are driving the continued growth and adoption of carrier screening across the globe.

Select Competitors (Total 42 Featured) -

  • 23andMe, Inc.
  • Abbott Laboratories
  • AutoGenomics, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Luminex Corporation
  • Myriad Genetics, Inc.
  • Sequenom, Inc.
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Carrier Screening - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Genetic Disorders Propels Growth in the Carrier Screening Market
    • Advances in Genomic Technologies Drive the Accuracy and Accessibility of Carrier Screening
    • Growing Adoption of Carrier Screening in Preconception and Prenatal Care Strengthens the Business Case for Genetic Testing
    • Technological Innovations in Next-Generation Sequencing (NGS) Accelerate Demand for Comprehensive Carrier Screening
    • Rising Incidence of Inherited Genetic Disorders Spurs Market Growth in Carrier Screening
    • Growing Demand for Personalized Medicine Generates Opportunities for Carrier Screening in Tailored Healthcare
    • Integration of AI and Data Analytics in Genetic Testing Enhances Efficiency and Interpretation of Carrier Screening Results
    • Rising Healthcare Expenditure and Insurance Coverage for Genetic Testing Sustain Growth in Carrier Screening Services
    • Expanding Use of Carrier Screening in Fertility Treatments Drives Demand in Assisted Reproductive Technology (ART)
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Carrier Screening Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Carrier Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Cystic Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Spinal Muscular Atrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Spinal Muscular Atrophy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gaucher Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gaucher Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Gaucher Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Tay-Sachs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Tay-Sachs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Tay-Sachs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Sickle Cell Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Molecular Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Molecular Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Molecular Screening Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Biochemical Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Biochemical Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Biochemical Screening Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • JAPAN
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • CHINA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • EUROPE
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Carrier Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • FRANCE
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • GERMANY
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Carrier Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • INDIA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: India 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Carrier Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Carrier Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • AFRICA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제